Anti-angiogenic therapies for metastatic colorectal cancer-Reference-Cited by-同舟云学术

Anti-angiogenic therapies for metastatic colorectal cancer

Published:2009-07-08 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Wagner Anna Dorothea ADW¹,Arnold Dirk²,Grothey Axel AG³,Haerting Johannes⁴,Unverzagt Susanne⁵

Affiliation:

1. Centre Hospitalier Universitaire Vaudois; Fondation du Centre Pluridisciplinaire d'Oncologie; Rue du Bugnon 46 Lausanne Switzerland 1011

2. Martin Luther University Halle Wittenberg; Department of Medicine IV; Ernst Grube Str 40 Halle/Saale Sachsen Anhalt Germany 06120

3. Mayo Clinic College of Medicine; Division of Medical Oncology; 200 First Street SW Rochester USA MN 55905

4. Martin Luther University Halle Wittenberg; Institute of Medical Epidemiology, Biostatistics and Informatics; Magdeburger Str 8 Halle (Saale) Sachsen Anhalt Germany 06112

5. Martin Luther University Halle-Wittenberg; Institute of Medical Epidemiology, Biostatistics and Informatics; Magdeburge Straße 8 Halle (Saale) Germany 06097

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD005392.pub3/fullpdf

Reference106 articles.

1. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.;Giantonio;Journal of Clinical Oncology,2007

2. Hecht JR Trarbach T Jaeger E Hainsworth J Wolff RA Lloyd K Bodoky G Borner M Laurent D Jacques C European Journal of Cancer Supplements 2007 238

3. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;The New England journal of medicine,2004

4. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer;Kabbinavar;Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology,2003

5. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial;Kabbinavar;Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology,2005

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Safety and Effectiveness of Bevacizumab in Metastatic Colorectal Cancer With Unresectable Metastases: A Real-Life Study From the South of Morocco;Cureus;2024-03-22

2. Pull the plug: Anti‐angiogenesis potential of natural products in gastrointestinal cancer therapy;Phytotherapy Research;2022-07-24

3. Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers;Expert Review of Clinical Pharmacology;2022-06-03

4. Bevacizumab in metastatic colorectal cancer in a real-life setting – toxicity profile, survival outcomes, and impact of tumor sidedness;Współczesna Onkologia;2022

5. Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study;BioDrugs;2021-05-20